|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
25 February 2020 |
|
Main ID: |
ChiCTR2000030173 |
|
Date of registration:
|
2020-02-24 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration
|
|
Scientific title:
|
Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration |
|
Date of first enrolment:
|
2020-02-17 |
|
Target sample size:
|
Experimental group:30;control group:30; |
|
Recruitment status: |
Pending |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=49229 |
|
Study type:
|
Interventional study |
|
Study design:
|
Parallel
|
|
Phase:
|
0
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Xue Zhigang
|
|
Address:
|
102 South Dongwu Road, Changsha Economic and Technological Development Zone, Changsha, Hu'nan, China
|
|
Telephone:
|
+86 15000285942 |
|
Email:
|
xuezg@tongji.edu.cn |
|
Affiliation:
|
Hu'nan Yuanpin Cell Biotechnology Co., Ltd |
|
|
Name:
|
Li Weilin
|
|
Address:
|
102 South Dongwu Road, Changsha Economic and Technological Development Zone, Changsha, Hu'nan, China
|
|
Telephone:
|
+86 18107490011 |
|
Email:
|
709374288@qq.com |
|
Affiliation:
|
Hu'nan Yuanpin Cell Biotechnology Co., Ltd |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Aged 18-60 years old;
2. Patients with clinical symptoms, signs, auxiliary detection combined with 1 or more nucleic acid test to confirm the diagnosis of new coronavirus pneumonia;
3. Voluntarily sign the informed consent to comply with the requirements of the program.
Exclusion criteria: 1. History of tumor;
2. Vascular embolism and pulmonary hypertension;
3. Suspected or established history of alcohol, drug or drug abuse;
4. Female patients of child-bearing age who are pregnant, breast-feeding or have a recent family planning;
5. Patients who have participated in or are participating in other drug trials within one month;
6. Patients considered unfit to participate in this clinical trial.
Age minimum:
18
Age maximum:
70
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Novel Coronavirus Pneumonia (COVID-19)
|
|
Intervention(s)
|
|
Experimental group:umbilical cord mesenchymal stem cells;control group:convention treatment;
|
|
Primary Outcome(s)
|
|
pulmonary function;Novel coronavirus pneumonic nucleic acid test;
|
|
Secondary Outcome(s)
|
|
pulmonary CT;pulmonary CT;chest radiography;
|
|
Source(s) of Monetary Support
|
|
Government support and enterprise self-financing
|
|
Ethics review
|
Status: Approved
Approval date: 03/02/2020
Contact:
Yan Tao
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|